Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Novantrone (mitoxantrone HCl) Injection February 2009
Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.
Genmab announces results of ofatumumab Phase II study in multiple sclerosis
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy.
Autoimmunity in visual loss.
Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS.
Anti-JCV antibody levels in serum or plasma further define risk of natalizumab-associated PML.
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study.
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
Multiple sclerosis: A lifestyle disease?
The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research.
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Keystone Symposium: Multiple Sclerosis
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial.
Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Role of regulatory b cells in neuroimmunologic disorders.
Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis.
Monoclonal antibodies in MS: mechanisms of action.

Pages